![]() | |
![]() | |
Clinical data | |
---|---|
Other names | 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a691004 |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 97% |
Elimination half-life | 22 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H27NO9 |
Molar mass | 497.500 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Idarubicin /ˌaɪdəˈruːbɪsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts [1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake. [2] Similar to other anthracyclines, it also induces histone eviction from chromatin. [3]
It belongs to the family of drugs called antitumor antibiotics.
It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia. [4]
It is used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis. [5]
It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
Diarrhea, stomach cramps, nausea and vomiting are common among patients treated with idarubicin. [6]
![]() | |
![]() | |
Clinical data | |
---|---|
Other names | 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a691004 |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 97% |
Elimination half-life | 22 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H27NO9 |
Molar mass | 497.500 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Idarubicin /ˌaɪdəˈruːbɪsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts [1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake. [2] Similar to other anthracyclines, it also induces histone eviction from chromatin. [3]
It belongs to the family of drugs called antitumor antibiotics.
It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia. [4]
It is used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis. [5]
It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
Diarrhea, stomach cramps, nausea and vomiting are common among patients treated with idarubicin. [6]